Centene Corporation (CNC)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-14
$67.66-2.52%
Close 2026-09-15 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-14
Research Workspace
Put CNC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 14% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 33% in its worst 12-month stretch.
View RiskCNC's growth relies on its ability to maintain strong revenue guidance and margin recovery. Revenue guidance was raised to $193.5-$197.5 billion, supporting a positive outlook. The stock trades at 12.8× P/E, below the peer median of 21.8×. This suggests the price reflects less growth than expected. If CNC cuts guidance, it could negatively impact the stock, with a 13% miss probability. Peer multiples imply a price about 43% above where it trades. This read is provisional.
Trailing returns as of 2026-09-15. CNC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 22 analysts currently covering CNC (as of Sep 2026).
Based on 13 Wall Street analysts offering 12-month price targets for CNC in the last 4 months.
Continue this research
Compare CNC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CNC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Managed Health Care — fair value, gap to price, and forward P/E.
Compare the value case
Put CNC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase 2026 adjusted diluted EPS guidance to > $4.80
Analysts support margin recovery, aiding EPS growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $67.66
The last 12 months of price, then the range of analyst 12-month targets from today’s $67.66.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
CFO departure may disrupt financial guidance execution.
New CFO could enhance financial oversight and strategy.
Advances: Increase 2026 total revenue guidance to $193.5-$197.5 billion
Raised 2026 revenue guidance positively impacts growth objectives.
Advances: Maintain disciplined SG&A expense ratio around 7.0%
Margin recovery supports disciplined SG&A expense management.
Advances: Increase 2026 total revenue guidance to $193.5-$197.5 billion
Improved outlook aligns with revenue growth target.
Advances: Increase 2026 total revenue guidance to $193.5-$197.5 billion
Q2 profit supports revenue growth guidance.
Advances: Increase 2026 adjusted EPS guidance to > $3.40
Strong earnings beat supports increased EPS guidance.